Your browser doesn't support javascript.
loading
Clinical utility of WHO-recommended screening tools and development and validation of novel clinical prediction models for pulmonary tuberculosis screening among outpatients living with HIV: an individual participant data meta-analysis.
Dhana, Ashar; Gupta, Rishi K; Hamada, Yohhei; Kengne, Andre P; Kerkhoff, Andrew D; Yoon, Christina; Cattamanchi, Adithya; Reeve, Byron W P; Theron, Grant; Ndlangalavu, Gcobisa; Wood, Robin; Drain, Paul K; Calderwood, Claire J; Noursadeghi, Mahdad; Boyles, Tom; Meintjes, Graeme; Maartens, Gary; Barr, David A.
Afiliación
  • Dhana A; Department of Medicine, University of Cape Town, Cape Town, South Africa ashardhana@live.com.
  • Gupta RK; Institute for Global Health, University College London, London, UK.
  • Hamada Y; Institute for Global Health, University College London, London, UK.
  • Kengne AP; Centre for International Cooperation and Global TB Information, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Kerkhoff AD; Non-communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.
  • Yoon C; Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, CA, USA.
  • Cattamanchi A; Department of Medicine, Division of Pulmonary and Critical Care Medicine and Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA.
  • Reeve BWP; Department of Medicine, Division of Pulmonary and Critical Care Medicine and Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA.
  • Theron G; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Ndlangalavu G; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Wood R; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Drain PK; Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Calderwood CJ; Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA, USA.
  • Noursadeghi M; Institute for Global Health, University College London, London, UK.
  • Boyles T; Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
  • Meintjes G; The Research Unit Zimbabwe, Biomedical Research and Training Institute, Harare, Zimbabwe.
  • Maartens G; Division of Infection and Immunity, University College London, London, UK.
  • Barr DA; Helen Joseph Hospital, Johannesburg, South Africa.
Eur Respir Rev ; 32(168)2023 Jun 30.
Article en En | MEDLINE | ID: mdl-37286216
ABSTRACT

BACKGROUND:

The World Health Organization (WHO) recommends that outpatient people living with HIV (PLHIV) undergo tuberculosis screening with the WHO four-symptom screen (W4SS) or C-reactive protein (CRP) (5 mg·L-1 cut-off) followed by confirmatory testing if screen positive. We conducted an individual participant data meta-analysis to determine the performance of WHO-recommended screening tools and two newly developed clinical prediction models (CPMs).

METHODS:

Following a systematic review, we identified studies that recruited adult outpatient PLHIV irrespective of tuberculosis signs and symptoms or with a positive W4SS, evaluated CRP and collected sputum for culture. We used logistic regression to develop an extended CPM (which included CRP and other predictors) and a CRP-only CPM. We used internal-external cross-validation to evaluate performance.

RESULTS:

We pooled data from eight cohorts (n=4315 participants). The extended CPM had excellent discrimination (C-statistic 0.81); the CRP-only CPM had similar discrimination. The C-statistics for WHO-recommended tools were lower. Both CPMs had equivalent or higher net benefit compared with the WHO-recommended tools. Compared with both CPMs, CRP (5 mg·L-1 cut-off) had equivalent net benefit across a clinically useful range of threshold probabilities, while the W4SS had a lower net benefit. The W4SS would capture 91% of tuberculosis cases and require confirmatory testing for 78% of participants. CRP (5 mg·L-1 cut-off), the extended CPM (4.2% threshold) and the CRP-only CPM (3.6% threshold) would capture similar percentages of cases but reduce confirmatory tests required by 24, 27 and 36%, respectively.

CONCLUSIONS:

CRP sets the standard for tuberculosis screening among outpatient PLHIV. The choice between using CRP at 5 mg·L-1 cut-off or in a CPM depends on available resources.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Tuberculosis Pulmonar / Infecciones por VIH Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Límite: Adult / Humans Idioma: En Revista: Eur Respir Rev Año: 2023 Tipo del documento: Article País de afiliación: Sudáfrica

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Tuberculosis Pulmonar / Infecciones por VIH Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Límite: Adult / Humans Idioma: En Revista: Eur Respir Rev Año: 2023 Tipo del documento: Article País de afiliación: Sudáfrica